December 2009
Worldwide Biotech;Dec2009, Vol. 21 Issue 12, p1
Trade Publication
The article reports on the collaborators selected by HealthLinx Limited for its second larger OvPlexâ„¢ ovarian cancer diagnostic trial. The countries where the trial will take place include Australia, Singapore and Great Britain. The study will focus on the detection of early stage symptomatic women. Some of the people who will work with HealthLinx on the trial include Professor Lewis Perrin, director of Gynaecological Oncology at Mater Hospital and Associate Professor Mahesh Choolani from the National University of Singapore.


Related Articles

  • Targeted treatment of folate receptor-positive platinum-resistant ovarian cancer and companion diagnostics, with specific focus on vintafolide and etarfolatide. Serpe, Loredana; Gallicchio, Margherita; Canaparo, Roberto; Dosio, Franco // Pharmacogenomics & Personalized Medicine;2014, Vol. 7, p31 

    Among the gynecological malignancies, ovarian cancer is the leading cause of mortality in developed countries. Treatment of ovarian cancer is based on surgery integrated with chemotherapy. Platinum-based drugs (cisplatin and carboplatin) comprise the core of first-line chemotherapy for patients...

  • Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Dreyling, M.; Ghielmini, M.; Marcus, R.; Salles, G.; Vitolo, U.; Ladetto, M. // Annals of Oncology;Sep2014 Supplement, Vol. 25 Issue suppl_3, piii76 

    No abstract available.

  • Jejunal Metastasis Colliding With a Borderline Tumor in the Ovary. Piana, Simonetta; Giunta, Alessandro; Valli, Riccardo // International Journal of Surgical Pathology;Oct2015, Vol. 23 Issue 7, p567 

    Metastatic adenocarcinomas to the ovary can show morphologically innocuous areas simulating primary benign lesions or borderline tumors. Ruling out a metastasis can be a difficult issue for pathologists, especially when facing with cystic tumors. Because of the important clinical implications of...

  • Targeted therapies and clinical trials in ovarian cancer†. Dancey, J. // Annals of Oncology;Dec2013 Supplement 10, Vol. 24, px59 

    Recent advances in molecular profiling have shown that cancers arising from the ovary are phenotypically and genetically heterogeneous. Within histologies, many mutations in druggable targets are uncommon in frequency but mutations leading to activation of specific signal transduction pathways...

  • Multilevel modeling and value of information in clinical trial decision support. Yuanyuan Cui; Murphy, Brendan; Gentilcore, Anastasia; Sharma, Yugal; Minasian, Lori; Kramer, Barnett S.; Coates, Paul M.; Gohagan, John K.; Klenk, Juergen; Tidor, Bruce // BMC Systems Biology;2014, Vol. 8 Issue 1, p157 

    Background Clinical trials are the main method for evaluating safety and efficacy of medical interventions and have produced many advances in improving human health. The Women's Health Initiative overturned a half-century of harmful practice in hormone therapy, the National Lung Screening Trial...

  • Lung Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Hocking, William G.; Ping Hu; Oken, Martin M.; Winslow, Stephen D.; Kvale, Paul A.; Prorok, Philip C.; Ragard, Lawrence R.; Commins, John; Lynch, David A.; Andriole, Gerald L.; Buys, Saundra S.; Fouad, Mona N.; Fuhrman, Carl R.; Isaacs, Claudine; Yokochi, Lance A.; Riley, Thomas L.; Pinsky, Paul F.; Gohagan, John K.; Berg, Christine D. // JNCI: Journal of the National Cancer Institute;5/19/2010, Vol. 102 Issue 10, p722 

    Background: The 5-year overall survival rate of lung cancer patients is approximately 15%. Most patients are diagnosed with advanced-stage disease and have shorter survival rates than patients with early-stage disease. Although screening for lung cancer has the potential to increase early...

  • Watch out for ovarian cancer's early signs.  // Australian Journal of Pharmacy;Feb2010, Vol. 91 Issue 1077, p21 

    The article reports on the early signs of ovarian cancer along with the call for pharmacists to instruct customers to have early detection test on the said disease for survival.

  • Screening strategy identified ovarian cancer early in postmenopausal women.  // Hem/Onc Today;11/25/2013, Vol. 14 Issue 22, p44 

    The author comments on a study by Karen H. Lu et al and published in a 2013 issue of "Cancer," which found the effectiveness of an ovarian cancer screening strategy that incorporates a CA-125 blood test and Risk of Ovarian Cancer Algorithm calculation in identifying ovarian cancer early in...

  • Abdominal symptoms are poor for predicting ovarian cancer, study finds. Mayor, Susan // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;2/6/2010, Vol. 340 Issue 7741, p284 

    The article focuses on a study which revealed that abdominal symptoms are poor basis for predicting ovarian cancer.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics